title: [Current status of post-infarction cardiogenic shock and revascularization].
abstract: Despite improved management of myocardial infarction, the incidence of cardiogenic shock remains constant at about 7.5% of cases. Patients who develop cardiogenic shock are older and much more often women. The site of infarction is usually anterior, transmural with greater left ventricular systolic dysfunction and a higher increase in cardiac enzymes. Diastolic intra-aortic balloon pumping is the usual treatment but survival only seems to be increased in patients undergoing revascularisation. Surgical revascularisation and circulatory assist devices have been proposed but patient selection in these studies was biased and optimised the results. The effect of thrombolysis was analysed in a subgroup of patients in the GISSI study. The 30 day mortality was 69.9% in 146 patients treated by streptokinase and 70.1% in patients given placebo. Thrombolysis only benefitted patients with an anterior myocardial infarction aged less than 65 and treated within 6 hours of the onset of pain. Although there are no randomised studies of the value of angioplasty in patients in cardiogenic shock. Several uncontrolled series suggest that this type of procedure reduces short and long-term mortality. However, the prognosis is not as good when unselected consecutive groups of patients are studied in whom infarction is complicated by cardiogenic shock immediately and who undergo "aggressive" revascularisation: 72% of patients die in hospital and there are few long-term survivors. The prognosis appears to be particularly poor in patients over 70 years of age with a previous history of myocardial infarction or who undergo prolonged pre-hospital cardiopulmonary resuscitation. However, the implantation of coronary stents associated with circulatory assist devices seems to improve the prognosis of infarction complicated by cardiogenic shock by ensuring adequate coronary flow and reducing the risk of reocclusion.
authors.affiliation: Service de cardiologie, CHU, Côte de Nacre, Caen.
authors.forename: G
authors.initials: G
authors.lastname: Grollier
authors.forename: E
authors.initials: E
authors.lastname: Saloux
authors.forename: E
authors.initials: E
authors.lastname: Lecluse
authors.forename: D
authors.initials: D
authors.lastname: Agostini
authors.forename: M
authors.initials: M
authors.lastname: Hamon
authors.forename: J C
authors.initials: JC
authors.lastname: Potier
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D009204:Myocardial Revascularization / Q000379:methods*; D018579:Patient Selection; D011379:Prognosis; D012737:Sex Factors; D012770:Shock, Cardiogenic / Q000209:etiology / Q000628:therapy*
chemical_list: D005343:Fibrinolytic Agents